<- Go Home
ArQule, Inc.
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.
Market Cap
$2.4B
Volume
1.9M
Cash and Equivalents
$42.2M
EBITDA
-$38.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$26.2M
Profit Margin
-547.98%
52 Week High
$20.45
52 Week Low
$3.15
Dividend
N/A
Price / Book Value
15.76
Price / Earnings
-58.12
Price / Tangible Book Value
15.76
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$38.2M
Return on Equity
-32.12%
Return on Assets
-16.32
Cash and Short Term Investments
$125.2M
Debt
$17.3M
Equity
$153.1M
Revenue
$4.8M
Unlevered FCF
-$16.3M
Sector
Biotechnology
Category
N/A